Tranquis Therapeutics, Inc.
Palo Alto, USA
|
Description:
​Tranquis Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a portfolio of small molecule therapeutics based on its unique approach of reprogramming dysfunctional myeloid immune cells to restore normal cell homeostasis and function. The company's lead candidate, TQS-168, completed phase 1 clinical development for the treatment of neurodegenerative disease, ALS. And the second candidate, TQS-621, has started IND-enabling work and is to be studied in a number of non-orphan...
​Tranquis Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a portfolio of small molecule therapeutics based on its unique approach of reprogramming dysfunctional myeloid immune cells to restore normal cell homeostasis and function. The company's lead candidate, TQS-168, completed phase 1 clinical development for the treatment of neurodegenerative disease, ALS. And the second candidate, TQS-621, has started IND-enabling work and is to be studied in a number of non-orphan...